M&A Deal Summary |
|
|---|---|
| Date | 2020-10-28 |
| Target | JT Pharmaceuticals - kappa opioid agonist peptide |
| Sector | Life Science |
| Buyer(s) | Titan Pharmaceuticals |
| Sellers(s) | JT Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 4 |
| Revenue | 1M USD (2020) |
Titan Pharmaceuticals is an operator of a commercial-stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. Titan Pharmaceuticals was founded in 1992 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: South Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
JT Pharmaceuticals, Inc. is an operator of a peptide drug development company focused on creating new drugs for acute, medically underserved, indications. JT Pharmaceuticals rapidly developing a nucleus of novel biotechnology companies and is primed for further expansion. JT Pharmaceuticals is based in Mt. Pleasant, South Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: South Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
